Kornimate/medical-research-clean huggingface dataset:
the migraine and pain study genebank at scripps clinic registry (maps)

Conditions: Migraine Disease

Summary: the objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.

it is estimated that over one-third of the world's population suffers from persistent or recurrent pain. migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. the blood or saliva samples will go through dna analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. by creating a maps genebank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.

Eligibility criteria:
inclusion criteria: 1. family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial 2. adolescent and at least 1 biologic parent with migraine diagnosis confirmed by dr. christy jackson 3. is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented 4. able to understand and grant informed consent exclusion criteria: 1. patient has been previously enrolled in the map genebank at scripps clinic registry 2. has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study 3. treatment with any investigational agents or devices within 30 days preceding enrollment in the study 4. has undergone ect within 90 days preceding enrollment in the study

Keywords: migraine
trauma triage decision with software (traumads)

Conditions: Trauma; Triage

Summary: it is intended to show that a computer software called trauma decision system (travmads) for the determination of the urgency of trauma patients who applied to emergency medical clinic gives more accurate, more objective, faster results than the triage scored by medical and non-medical personnel and to show the fact that traumads provides more patient satisfaction.

there are limitations in our routine standard of practice in emergency medical clinic in rapid triage about the adequacy particularly in the patient group where specific and rapid decision-making, such as trauma. the process of evaluating the patients who are directed to the green area unnecessarily in trauma care by the physician is prolonged, the evaluation process of patients who are directed to the red area unnecessarily shortens but hospital resources are being used extensively. therefore, in this study, it was planned to perform objective triage with a computer based scoring system. triage scoring determined by the ministry of health (sb ), routinely performed by an emergency medical technician (emt), will be applied when the patients are admitted to emergency services. according to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded. to the other group, triage maintenance / evaluation will be done with computer software developed by us. all patients with trauma should be included in the study, demographic data, trauma mechanism and trauma type vital signs at the time of application of the patients will be routinely observed in both groups of patients. these observations are routine for this disease group and we will not undertake any interventional procedures or screening except special routine application for research purposes. the observation and file information will be organized by the triage staff in both groups at the time of the application of the patients. in this software-based program before working on the software informative training will be given to triage staff and for this patient triage handheld computers will be given to triage staff. in order for the referring patients to be able to see the entries made with the triage software a simultaneous large-screen monitor will be used. at the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. as a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.

Eligibility criteria:
inclusion criteria: * all trauma patients who want to participate exclusion criteria: * who do not want to participate, who are not triaged, who leave the hospital before the treatment is completed

Keywords: trauma triage software emergency
assessment of novel sound changing principles in hearing instruments to determine their application - sonova2018_31

Conditions: Hearing Loss

Summary: a methodical evaluation of sound changing principles in ce-labelled sonova brand hearing instruments (e.g. phonak hearing instruments) is intended to be conducted on hearing impaired participants. these sound changing principles are enabled by respective hearing instrument technologies and hearing instrument algorithms. the aim of the study is to investigate and asses strength and weaknesses of these sound changing principles in terms of hearing performance to determine their application in hearing instruments (phase of development). objective laboratory measurements will be carried out. this will be a controlled, single blinded and randomised active comparator clinical evaluation which will be conducted mono centric at sonova ag headquarter based in stäfa


Eligibility criteria:
inclusion criteria: * adult hearing impaired persons (minimum age: 18 years) with or without experience with hearing aids * sensorineural hearing loss (n4-n6 according to iso 60118-15) * good written and spoken (swiss) german language skills * healthy outer ear * informed consent as documented by signature * symmetric hearing loss below 1000 hz exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments on study site * inability to produce a reliable hearing test result * known psychological problems * central hearing disorders
augmentin 1gm in skin and soft tissue infection

Conditions: Skin Diseases, Infectious; Infection, Soft Tissue

Summary: study to evaluate the effects of augmentin 1gm in the treatment of skin and soft tissue infections


Eligibility criteria:
inclusion criteria: * having diagnosed uncomplicated soft tissue infection (e.g furuncle, cellulitis) * has given freely documented consent. exclusion criteria: * antibiotics * have renal or hepatic insufficiency * systemic toxicity * pregnancy * lactation * hypersensitivity to penicillin or beta-lactam antibiotics

Keywords: skin augmentin 1gm soft tissue infections
signia stapler versus vessel sealer extend energy device with sureform stapling in robotic-assisted segmentectomy

Conditions: Lung Cancer; Thoracic Cancer; Lung Neoplasm

Summary: robotic-assisted thoracoscopic surgery (rts) segmentectomy is safe and effective for patients with early-stage non-small cell lung cancer (nsclc). in rts-segmentectomy, dissection and sealing procedures are performed by either staplers or energy devices. staplers, the current standard of care, have been associated with higher operating costs compared to energy devices for open lobectomy, rts lobectomy and minimally invasive segmentectomy. however, there is a lack of prospective research evaluating the costs of the two methods for lung dissection and vessel sealing in rts-segmentectomy. this prospective trial seeks to determine whether it is feasible to conduct a randomized controlled trial evaluating the costs of the signia stapler versus vessel sealer extend energy device in rts-segmentectomy for nsclc. if this trial is feasible, we will be able to conduct a full-scale trial to compare costs and health outcomes, providing an economic evaluation that will inform hospital decision makers and clinicians in canada.


Eligibility criteria:
inclusion criteria: * age between 18 and 120 years at time of consent * ability to speak and understand english * clinical stage i, ii or iiia nsclc * candidate for rts segmentectomy, as determined by the operating surgeon exclusion criteria: * anticoagulation with inability to cease anticoagulant therapy prior to surgery * incurable coagulopathy * systemic vascular disease or vasculitis * not a candidate for rts segmentectomy
analysis of breath sound during thoracic surgery

Conditions: Thoracic Surgery

Summary: in modern thoracic surgery, double-lumen endobronchial tube (dlet) is the first choice for intubation. one lung ventilation can be perfectly performed by dlet, with the benefit of maintaining adequate gas exchange and establishing great surgical field. traditionally, we use stethoscope and fiberscope for dlet site evaluation. however, there are some concerns over traditional methods. stethoscope evaluation can be subjective from person to person; fiberscope, on the other hand, can cause additional bronchial injury as it is an invasive procedure. we hope to utilize patches, also known as electronic stethoscope, which provide non-invasive and visualized spectrum information, to assist anesthesiologists evaluate dlet insertion site more precisely in patients undergo thoracic surgery.

this is an observational study. we use electronic stethoscope, which stick on patient's anterior chest, to record breath sound after intubation. the soundtrack will then be transformed to visualized waveform, enabling us to analyze and compare with actual result confirmed by fiberscope.

Eligibility criteria:
inclusion criteria: * patients undergo thoracic surgery and general anesthesia using dlet exclusion criteria: * patients have no will to participate * vulnerable groups, including physically disabled and mental diseased patients * patients with abnormal breath sound, pulmonary disease or history of cardiothoracic surgery

Keywords: double lumen endobronchial tube stethoscope fiberscope electronic stethoscope
metabolic and cardiovascular impact of cd36 deficiency in african americans

Conditions: Obesity

Summary: cd36, a protein that facilitates tissue uptake of fat, as a common link between blood fat concentrations and metabolic disease states such as diabetes mellitus. genetic variants in the cd36 gene are more common in african americans compared to whites and it may confer protection against metabolic diseases by altering the amount of fat in the blood. the purpose of this study is to compare the levels of fat in the blood and to assess endothelial dysfunction among carriers versus non-carriers of the coding snp, rs3211938 of the cd36 gene after a high fat meal challenge


Eligibility criteria:
inclusion criteria: * african american men and women age 18-65 years of age * bmi 25-45 kg/m2 exclusion criteria: * diabetes * pregnancy * use of nicotinic acid for dyslipidemia * history of nutrient malabsorption * clinically significant hepatic or renal disease, or serum creatinine or liver function tests \> 2times upper limits of normal * symptomatic acute or chronic gallbladder disease * any underlying or acute disease requiring regular medication which could in the principal investigator's opinion possibly pose a threat to the subject or make implementation of the protocol difficult * mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study * patient unwilling or unable to give informed consent
radiotherapy patient education with virtual reality

Conditions: Anxiety; Cancer

Summary: the purpose of this research study is to investigate the impact of virtual reality experiences on individuals undergoing radiotherapy, aiming to assess whether this immersive technology can reduce anxiety and enhance patient overall treatment satisfaction. by comparing different virtual reality techniques and a standard informational video, the study seeks to identify optimal strategies for leveraging virtual reality to improve the patient experience during radiotherapy.


Eligibility criteria:
inclusion criteria: 1. histologically proven cancer 2. ≥18 years of age 3. able to speak and read english and/or spanish 4. receiving radiotherapy at the university of miami exclusion criteria: 1. prior radiation therapy 2. pregnant or nursing women 3. men or women of childbearing potential who are unwilling to employ adequate contraception 4. patients unable to consent or are prisoners 5. participants with impaired decision-making capacity 6. any serious illness or medical condition that would compromise patient safety during virtual reality as judged by the treating physician 7. unwilling or unable to watch virtual reality video 8. unwilling to fill out survey forms
wecare study in gastric cancer survivors

Conditions: Gastric Cancer

Summary: the korean quality of life in stomach cancer patients study group (koquss) made a method (koquss-40) for assessing appropriately the quality of life of gastric cancer patients who have undergone gastrectomy, and developed a digital platform (wecare) based on koquss-40. in this study, we propose a randomized controlled trial to compare quality of life after gastrectomy in patients with and without smartphone app support.

smartphone apps have been gaining popularity in the delivery of lifestyle interventions in chronic disease management. in patients with cancer, randomized clinical trials have investigated the effect of smartphone-based interventions and reported improved quality of recovery and equal satisfaction with care compared with conventional in-person follow-up. however, there are no studies yet in which smartphone apps have evaluated the quality of life in patients after gastric cancer surgery. surgery is the mainstay of gastric cancer treatment. the proportion of patients with early gastric cancer and their survival rate of gastric cancer patients are increasing in east asia thanks to the nationwide endoscopy screening program. as the number of long-term survivors after gastric cancer surgery increases, interest in the quality of life after surgery is also increasing. after gastrectomy, the remaining stomach volume is reduced or lost, and the vagus nerve is damaged during the surgery, which has various effects on the motor function and hormone secretion function of the stomach. patients experience postgastrectomy syndrome, which includes lethargy, decreased appetite, early satiety, weight loss, abdominal distension, gastroesophageal reflux symptoms, diarrhea, anemia, and dumping syndrome. in addition to these physical symptoms, patients experience various symptoms and aftereffects after stomach cancer surgery, including psychological reactions such as fear, anxiety, and depression, and social problems such as avoidance of interpersonal relationships, social isolation, and difficulty returning to society.

Eligibility criteria:
inclusion criteria: * adult patient (19-75 years) who underwent radical gastrectomy exclusion criteria: * patients who were unable to undergo regular follow-up, lacked communication, or were deemed unsuitable to participate in this study by the researcher
ramp 200 / ramp cardiovascular tests at the point-of-care

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Heart Failure; Congestive Heart Failure

Summary: this clinical investigation is designed to demonstrate the performance characteristics of the ramp® cardiac tests analyzed on the ramp® 200 by non-laboratorial operators at the point-of-care when compared to the results for the same samples analyzed on the ramp® reader.


Eligibility criteria:
inclusion criteria: study arms a - troponin i (acs/mi) 1. males or females, 18 years of age or older, of any race 2. has had a routine test order of troponin for suspected acute coronary syndrome / myocardial infarction (acs/mi) - as per institutional guidelines 3. willing to voluntarily agree to sign a consent form (if applicable) study arms b - myoglobin (acs/mi) 1. males or females, 18 years of age or older, of any race 2. has had a routine test order of troponin for suspected acute coronary syndrome / myocardial infarction (acs/mi) - as per institutional guidelines 3. myoglobin test result falls within the reportable range of the test as reported in the ramp® myoglobin ifu. 4. willing to voluntarily agree to sign a consent form (if applicable) study arms c - ck-mb (acs/mi) 1. males or females, 18 years of age or older, of any race 2. has had a routine test order of troponin for suspected acute coronary syndrome / myocardial infarction (acs/mi) - as per institutional guidelines 3. ck-mb test result falls within the reportable range of the test as reported in the ramp® ck-mb ifu. 4. willing to voluntarily agree to sign a consent form (if applicable) study arm d - nt-probnp (hf) 1. males or females, 18 years of age or older, of any race 2. has had a routine test order of nt-probnp or bnp for suspected heart failure (hf) - as per institutional guidelines 3. willing to voluntarily agree to sign a consent form (if applicable) exclusion criteria: study arms a, b, c - troponin i, myoglobin, ck-mb (acs/mi) 1. healthy subjects 2. pregnant or lactating 3. subjects not having a cardiac marker test ordered 4. blood sample collected \>24 hours prior to screening 5. subjects without adequate volumes of surplus edta whole blood available for all required trial testing 6. non-compliance to the protocol or the inclusion criteria study arm d - nt-probnp (hf) 1. healthy subjects 2. pregnant or lactating 3. subjects not having a cardiac marker test ordered 4. blood sample collected \>24 hours prior to screening 5. subjects without adequate volumes of surplus edta whole blood available for all required trial testing 6. non-compliance to the protocol or the inclusion criteria
reduction bleeding in laminectomy with double doses of tranexamic acid

Conditions: Bleeding

Summary: tranexamic acid has benn widely used to reduce perioperative bleeding in several operations such as cardiac surgery, liver transplant and joint arthroplasty with good results. few studies in laminectomy had conflicting results and varying in doses. the objective is to compare perioperative bleeding in major laminectomy between patients receive doubles doses of tranexamic acids (15 mg/kg and 15 mg/kg) with who receive pacebo (0.9% nacl).

78 patients undergoing major laminectomy (with instrumentation or equal or more than 3 levels laminectomy) will be enrolled. we exclude patients who age over 65, anemia, allergy to tranexamic acid, history of deep vein thormbosis (dvt), ischemic heart disease (ihd), pulmonary embolism (pe), strokes, liver disease, chronic kidney disease with creatinine \>2.0 mg/dl, and coagulopathy. after randomization, before induction and 3 hour after the first dose, patients will receive study drug or placebo intravenously. the standard anesthesia and monitoring will be tha same for all of the patients. perioperative mild hypotensive technique will be used with the mean arterial pressure more than 60 mmhg and nearly the end, the blood pressure will be back to normal for the bleeding check. hematocrit will be monitored at the begining and every two hours. blood will be given if the hematocrit is below 30%. the perioperative fluid will be managed by anesthesiologist who will not know the patients' groups. the next morning, the hematocrit and blood creatinine will be checked and if the hematocrit is lower than 30%, blood will be given. perioperative blood loss, total fluid and blood transfusion within 24 hours will be recorded. if there are any suspected symptoms and signs of dvt, angina, chf, pe, strokes or other complications, the necessory investigations will be done for the definite dignosis and the appropriate treatment will be started immediately.

Eligibility criteria:
inclusion criteria: * has laminectomy with instrumentation or equal or more than 3 levels laminectomy * age 18-65 years * asa 1-3 * elective operation exclusion criteria: * allergy to tranexamic acid * anemia (hb\<12 g/dl in female or hb\<13 g/dl in male) * history of cvt, ihd, pe, strokes * liver disease * chronic kidney disease with creatinie\>2.0 mg/dl * receive anticoagulant or coagulopathy

Keywords: tranexamic acid bleeding blood transfusion spine surgery
high dose risankizumab for psoriasis

Conditions: Psoriasis

Summary: this is a pilot study that explores whether higher initial doses of risankizumab (300 mg and 600 mg, 2 times and 4 times the standard initial doses for plaque psoriasis) can more effectively target resident memory t cells, a type of immune cell within psoriatic lesions, and whether this results in higher levels of completely clear skin and for longer periods of time following withdrawal of drug. it is believed that resident memory t cells in psoriatic skin contribute to the persistence of psoriasis. it is believed that if the study drug can more effectively eliminate these cells, better clearance of psoriasis may be achieved (when compared to standard initial doses of study drug).


Eligibility criteria:
inclusion criteria: * subject has provided written consent * subject has the ability to comply with all study visits and procedures * subject is at least 18 years of age * subject has chronic stable plaque psoriasis for at least 6 months and with a severity of bsa greater than or equal to 10 and pasi greater than or equal to 12 * female subjects of child-bearing potential must have a negative urine test at screening and baseline. female subjects must be either postmenopausal, or permanently surgically sterile, or for women of child-bearing potential practicing at least one form of birth control exclusion criteria: * breastfeeding or pregnant women, or women who plan to become pregnant during study period * participation in any other clinical trial * active infection with hiv, hepatitis b virus, or hepatitis c virus * active infection with tuberculosis or untreated latent tuberculosis * history of known active cancer, other than non-melanoma skin cancer or cervical carcinoma in situ, in the past 3 years * history of drug or alcohol abuse in the past 6 months, as per investigator's assessment * history of suicidal ideation or attempts in the past 6 months * presence of any concurrent illness, which in the opinion of the investigator, would place the patient at unnecessary safety risk during the trial or interfere with completion of the trial * treatment with topical medications for psoriasis in the past 2 weeks * treatment with oral medications for psoriasis in the past 4 weeks * phototherapy for psoriasis in the past 4 weeks * any prior treatment with risankizumab * treatment with biologic medications for psoriasis (other than risankizumab) in the past 4 months

Keywords: psoriasis risankizumab plaque skyrizi